Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Overview

This protocol outlines a nine-day method for the transduction and expansion of rhesus macaque peripheral blood mononuclear cells (PBMCs) to produce immunotherapeutic T-cells. The resulting T-cells express an antiviral chimeric antigen receptor and a chemokine receptor CXCR5, targeting lymphoid follicles and showing potential for long-term persistence after infusion.

Key Study Components

Area of Science

• Immunotherapy
• Cellular Biology
• Gene Therapy

Background

• Rhesus macaque PBMCs are used to produce T-cells for therapeutic applications.
• The protocol aims to enhance the efficacy of T-cell infusions against diseases like HIV.
• Healthy stimulated PBMCs are crucial for successful transduction.
• Adaptation of this method for human cells could lead to significant advancements in HIV treatment.

Purpose of Study

• To develop a reliable protocol for producing transduced T-cells.
• To evaluate the co-expression of therapeutic genes in T-cells.
• To assess the potential for long-term persistence of these cells post-infusion.

Methods Used

• Thawing and stimulating primary rhesus PBMCs.
• Transduction using retroviral vectors.
• Flow cytometry for monitoring gene expression and cell viability.
• Expansion of transduced cells in growth media.

Main Results

• A median density of 55.6 million cells per well was achieved after four days.
• Cell viability ranged from 83% to 95% throughout the protocol.
• On day five, 42.8% of cells co-expressed the transduced genes, increasing to 47.6% by day nine.
• Flow cytometry confirmed the maintenance of a central memory phenotype.

Conclusions

• The protocol successfully produces T-cells with desired characteristics for immunotherapy.
• Adaptations for human cells could enhance treatment options for HIV.
• Future studies may explore the application of this method to other therapeutic targets.

Frequently Asked Questions